We are live on ! Find out more
WFM

Wilmington Funds Management Portfolio holdings

AUM $988M
1-Year Est. Return 26.05%
This Fund
S&P 500
This Quarter Est. Return
+4.48%
1 Year Est. Return
+26.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$988M
AUM Growth
+$67.7M
Cap. Flow
+$35.7M
Cap. Flow %
3.61%
Top 10 Hldgs %
10.81%
Holding
873
New
103
Increased
253
Reduced
220
Closed
127

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.38M
2
AGN
Allergan Inc
AGN
+$5.74M
3
OII icon
Oceaneering
OII
+$4.45M
4
FRX
FOREST LABORATORIES INC
FRX
+$3.94M
5
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
+$3.61M

Top Sells

Rank Stock Value
1
CTXS
Citrix Systems Inc
CTXS
+$5.03M
2
XOM icon
ExxonMobil
XOM
+$4.42M
3
GE icon
GE Aerospace
GE
+$3.28M
4
CVX icon
Chevron
CVX
+$2.84M
5
HLF icon
Herbalife
HLF
+$2.82M

Sector Composition

Rank Sector Weight
1 Industrials 15.33%
2 Consumer Discretionary 12.29%
3 Healthcare 11.76%
4 Technology 11.66%
5 Real Estate 9.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FTR
726
DELISTED
Frontier Communications Corp.
FTR
$61K 0.01%
700
-740
-51% -$64K
HOV icon
727
Hovnanian Enterprises
HOV
$800M
$57K 0.01%
439
– –
SGYP
728
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$55K 0.01%
+13,440
New +$57.1K
AMD icon
729
Advanced Micro Devices
AMD
$741B
$54K 0.01%
12,850
– –
CIM
730
Chimera Investment
CIM
$1.06B
$50K 0.01%
1,047
– –
CBB
731
DELISTED
Cincinnati Bell Inc.
CBB
$49K 0.01%
2,476
– –
ANV
732
DELISTED
Allied Nevada Gold Corp
ANV
$43K ﹤0.01%
+11,340
New +$39.4K
QMCO icon
733
Quantum Corp
QMCO
$444M
$42K ﹤0.01%
+218
New +$39.8K
TCRT icon
734
Alaunos Therapeutics
TCRT
$4.64M
$42K ﹤0.01%
69
– –
ACI
735
DELISTED
ARCH COAL, INC.
ACI
$38K ﹤0.01%
1,030
– –
ENTR
736
DELISTED
ENTROPIC COMMUNICATIONS INC COM STK (DE)
ENTR
$38K ﹤0.01%
+11,340
New +$39.8K
MRGE
737
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$38K ﹤0.01%
16,900
+5,750
+52% +$13.1K
DVAX
738
DELISTED
Dynavax Technologies
DVAX
$34K ﹤0.01%
2,141
– –
CDMO
739
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$33K ﹤0.01%
+2,529
New +$31.9K
PCO
740
DELISTED
Pendrell Corporation - Class A
PCO
$33K ﹤0.01%
+19
New +$31.4K
RXII
741
DELISTED
GALENA BIOPHARMA INC COM
RXII
$33K ﹤0.01%
10,700
– –
PSTV icon
742
Plus Therapeutics
PSTV
$25.9M
– –
0
– –
AOI
743
DELISTED
Alliance One International
AOI
$31K ﹤0.01%
+1,257
New +$33.1K
ACLS icon
744
Axcelis
ACLS
$3.69B
$23K ﹤0.01%
2,850
– –
ZGNX
745
DELISTED
Zogenix, Inc.
ZGNX
$20K ﹤0.01%
1,250
– –
PRKR
746
DELISTED
Parkervision Inc
PRKR
$16K ﹤0.01%
1,113
– –
ACHV icon
747
Achieve Life Sciences
ACHV
$634M
– –
-5
Closed -$124K
AEE icon
748
Ameren
AEE
$31.1B
– –
-6,450
Closed -$266K
AES icon
749
AES
AES
$10.6B
– –
-19,910
Closed -$284K
AGNC icon
750
AGNC Investment
AGNC
$12.9B
– –
-9,500
Closed -$204K
28 29
30
31 32

Similar funds

SCM
Stux Capital Management New York $766M AUM 28.03% 1-Year Est. Return
MIU
Man Investments (UK) London, United Kingdom $1.29B AUM 31.85% 1-Year Est. Return
SR
Swiss Reinsurance Zurich, Switzerland $664M AUM 11.24% 1-Year Est. Return
CH
Cavalane Holdings Sydney, Australia $558M AUM
WTIM
Wilmington Trust Investment Management Wilmington, Delaware $492M AUM 25.19% 1-Year Est. Return
FOAM
Five Oceans Asset Management Sydney, Australia $438M AUM 24.83% 1-Year Est. Return
BII
Baring International Investment London, United Kingdom $1.57B AUM 24.97% 1-Year Est. Return
HGI
Hansberger Global Investors Ft Lauderdale, Florida $354M AUM 17.2% 1-Year Est. Return

Wilmington Funds Management's Q2 2014 Portfolio in Review

As of Q2 2014, Wilmington Funds Management held 873 positions worth $988M, up 7.4% from $920M the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Wilmington Funds Management deployed $35.7M of net new capital in Q2 2014, opening 103 new positions and adding to 253 existing holdings. Its largest new stake was AstraZeneca: 88,300 shares worth $6.56M.

By sector, the portfolio is most concentrated in Industrials at 15% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Citrix Systems Inc, an estimated $5.03M trimmed.

  • Wilmington Funds Management's largest Q2 2014 buy was AstraZeneca: 88,300 shares worth $6.56M.
  • Wilmington Funds Management added most to Allergan Inc in Q2 2014, an estimated $5.74M increase.
  • Wilmington Funds Management's biggest Q2 2014 reduction was Citrix Systems Inc, cutting an estimated $5.03M.
  • Wilmington Funds Management fully exited Wolfspeed in Q2 2014, selling an estimated $1.9M.
  • Wilmington Funds Management's ten largest holdings make up 11% of its $988M portfolio in Q2 2014.
  • Wilmington Funds Management opened 103 new positions and closed 127 in Q2 2014.
  • Wilmington Funds Management's portfolio value rose 7.4% quarter-over-quarter to $988M.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.